+

WO2000061766A3 - Vaccin anticancereux specifique de la telomerase - Google Patents

Vaccin anticancereux specifique de la telomerase Download PDF

Info

Publication number
WO2000061766A3
WO2000061766A3 PCT/IB2000/000610 IB0000610W WO0061766A3 WO 2000061766 A3 WO2000061766 A3 WO 2000061766A3 IB 0000610 W IB0000610 W IB 0000610W WO 0061766 A3 WO0061766 A3 WO 0061766A3
Authority
WO
WIPO (PCT)
Prior art keywords
telomerase
cancer vaccine
specific cancer
useful
antigens
Prior art date
Application number
PCT/IB2000/000610
Other languages
English (en)
Other versions
WO2000061766A2 (fr
Inventor
Babita Agrawal
Bryan Michael Longenecker
Original Assignee
Biomira Inc
Babita Agrawal
Bryan Michael Longenecker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc, Babita Agrawal, Bryan Michael Longenecker filed Critical Biomira Inc
Priority to AU41394/00A priority Critical patent/AU781376B2/en
Priority to JP2000611689A priority patent/JP2002541811A/ja
Priority to CA002368967A priority patent/CA2368967A1/fr
Priority to EP00920996A priority patent/EP1171612A2/fr
Publication of WO2000061766A2 publication Critical patent/WO2000061766A2/fr
Publication of WO2000061766A3 publication Critical patent/WO2000061766A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des antigènes des lymphocytes T spécifiques de la télomerase utiles dans la génération de réponses des lymphocytes T à la télomérase. Les formulations d'antigènes de la télomérase comme vaccins servent à traiter et prévenir le cancer grâce à des techniques in vivo ou ex vivo.
PCT/IB2000/000610 1999-04-09 2000-04-07 Vaccin anticancereux specifique de la telomerase WO2000061766A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU41394/00A AU781376B2 (en) 1999-04-09 2000-04-07 Telomerase-specific cancer vaccine
JP2000611689A JP2002541811A (ja) 1999-04-09 2000-04-07 テロメラーゼ特異的癌ワクチン
CA002368967A CA2368967A1 (fr) 1999-04-09 2000-04-07 Vaccin anticancereux specifique de la telomerase
EP00920996A EP1171612A2 (fr) 1999-04-09 2000-04-07 Vaccin anticancereux specifique de la telomerase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12853999P 1999-04-09 1999-04-09
US60/128,539 1999-04-09

Publications (2)

Publication Number Publication Date
WO2000061766A2 WO2000061766A2 (fr) 2000-10-19
WO2000061766A3 true WO2000061766A3 (fr) 2001-03-08

Family

ID=22435817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000610 WO2000061766A2 (fr) 1999-04-09 2000-04-07 Vaccin anticancereux specifique de la telomerase

Country Status (5)

Country Link
EP (1) EP1171612A2 (fr)
JP (1) JP2002541811A (fr)
AU (1) AU781376B2 (fr)
CA (1) CA2368967A1 (fr)
WO (1) WO2000061766A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560437B2 (en) 1996-10-01 2009-07-14 Geron Corporation Nucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
AU734089B2 (en) 1996-10-01 2001-06-07 Geron Corporation Human telomerase catalytic subunit
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
AU3456099A (en) * 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
EP1257284A4 (fr) * 2000-02-15 2005-12-21 Univ California Vaccin universel et methode de traitement du cancer utilisant la transcriptase inverse de la telomerase
CA2399816A1 (fr) 2000-02-15 2001-08-23 Regents Of The University Of California Vaccin universel et methode de traitement du cancer utilisant la transcriptase inverse de la telomerase
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
AU2002311616B2 (en) * 2001-06-25 2007-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparation of vesicles loaded with biological material and different uses thereof
DE102006025146A1 (de) * 2006-05-30 2007-12-06 Charité - Universitätsmedizin Berlin Peptide zur differentiellen Modulation der proteasomalen Aktivität
EP1887084A1 (fr) 2006-08-10 2008-02-13 International Investment and Patents SA Plasmides avec l'action immunologique
WO2014079464A1 (fr) * 2012-11-21 2014-05-30 Sherif Salah Abdul Aziz Nouvelles compositions enzymatiques pour le traitement d'une infection par le virus de l'immunodéficience humaine (vih)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014592A2 (fr) * 1996-10-01 1998-04-09 Geron Corporation Transcriptase inverse de la telomerase
WO1998050527A1 (fr) * 1997-05-08 1998-11-12 Biomira Inc. Procede de generation de cellules t activees et de cellules de presentation d'antigene et a impulsion antigenique
WO1999050392A1 (fr) * 1998-03-31 1999-10-07 Geron Corporation Techniques et compositions permettant de faire apparaitre une reponse immunitaire a un antigene de telomerase
WO2000002581A1 (fr) * 1998-07-08 2000-01-20 Norsk Hydro Asa Peptides antigenes derivees de la telomerase
WO2000025813A1 (fr) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute IMMUNOTHERAPIE ET DIAGNOSTIC DU CANCER AU MOYEN D'ANTIGENES UNIVERSELS ASSOCIES A DES TUMEURS TELS QUE hTERT

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014592A2 (fr) * 1996-10-01 1998-04-09 Geron Corporation Transcriptase inverse de la telomerase
WO1998050527A1 (fr) * 1997-05-08 1998-11-12 Biomira Inc. Procede de generation de cellules t activees et de cellules de presentation d'antigene et a impulsion antigenique
WO1999050392A1 (fr) * 1998-03-31 1999-10-07 Geron Corporation Techniques et compositions permettant de faire apparaitre une reponse immunitaire a un antigene de telomerase
WO2000002581A1 (fr) * 1998-07-08 2000-01-20 Norsk Hydro Asa Peptides antigenes derivees de la telomerase
WO2000025813A1 (fr) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute IMMUNOTHERAPIE ET DIAGNOSTIC DU CANCER AU MOYEN D'ANTIGENES UNIVERSELS ASSOCIES A DES TUMEURS TELS QUE hTERT

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
40th Annual Meeting of the American Society of Hematology;Miami Beach, Florida, USA; December 4-8, 1998 *
GAGLIARDI M C ET AL: "Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro", INTERNATIONAL IMMUNOLOGY, vol. 7, 1995, pages 1741 - 1752, XP002078855, ISSN: 0953-8178 *
MINEV BORIS ET AL: "Cytotoxic T cell immunity against telomerase reverse transcriptase in humans.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 9, 25 April 2000 (2000-04-25), pages 4796 - 4801, XP002155017, ISSN: 0027-8424 *
VONDERHEIDE R H ET AL: "Search for universal tumor antigens: Potential of the catalytic telomerase subunit.", BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), pages 500A, XP000971197, ISSN: 0006-4971 *
VONDERHEIDE R H ET AL: "THE TELOMERASE CATALYTIC SUBUNIT IS A WIDELY EXPRESSED TUMOR- ASSOCIATED ANTIGEN RECOGNIZED BY CYTOTOXIC T LYMPHOCYTES", IMMUNITY, vol. 10, no. 6, June 1999 (1999-06-01), pages 673 - 679, XP000890114, ISSN: 1074-7613 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560437B2 (en) 1996-10-01 2009-07-14 Geron Corporation Nucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase

Also Published As

Publication number Publication date
AU781376B2 (en) 2005-05-19
JP2002541811A (ja) 2002-12-10
AU4139400A (en) 2000-11-14
CA2368967A1 (fr) 2000-10-19
WO2000061766A2 (fr) 2000-10-19
EP1171612A2 (fr) 2002-01-16

Similar Documents

Publication Publication Date Title
WO2000061766A3 (fr) Vaccin anticancereux specifique de la telomerase
WO1999033488A3 (fr) Vaccin
IL145982A0 (en) Vaccines
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
WO2001070275A3 (fr) Conjugues de la camptothecine-acide polyglutamique et leurs procedes de preparation
WO2002076404A3 (fr) Conjugues d'agents pharmaceutiques et d'alcools gras
EP2283866A3 (fr) Procédés de traitement utilisant des conjugués maytansinoïdes-anticorps anti-ERBB
EP1409547A4 (fr) Procedes et compositions pharmaceutiques permettant la falsification immunitaire, particulierement utiles pour le traitement du cancer
WO2001000232A3 (fr) Vaccin
HUP0401753A3 (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
WO2004045529A3 (fr) Vaccin contre le virus du nil occidental
WO2001062283A3 (fr) Nouvelle formulation d'adjuvant des muqueuses, non antigenique, modulant l'effet de substances, y compris d'antigenes de vaccin, en contact avec les surfaces de muqueuses
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
WO2002034773A3 (fr) Genes streptococciques
GB2370772B (en) Acellular immunogenic compositions and acellular vaccine compositions against bacillus anthracis
MXPA02012249A (es) Peptidos, composiciones y metodos para el tratamiento de burkholderia cepacia.
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2000053231A3 (fr) Conjugues d'acides gras et d'agents anticancereux, et utilisations correspondantes
WO2003094828A3 (fr) Vaccins contre le cancer et methodes d'utilisation desdits vaccins
WO2002076485A3 (fr) Vaccin assurant la modulation entre des reponses immunitaires t1 et t2
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
AU2001238493A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2002000844A3 (fr) Adjuvants de vaccins polynucleotidiques et formulations contenant des tensioactifs cationiques, procedes d'utilisation associes
WO2001037862A3 (fr) Vaccin a base de lactobacilles pour le traitement des inflammations de la prostate et de l'hyperplasie benigne de la prostate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2368967

Country of ref document: CA

Ref country code: CA

Ref document number: 2368967

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 611689

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000920996

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000920996

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09958398

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000920996

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载